Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy

We measured brain acetylcholinesterase activity in 16 patients with Parkinson's disease (PD), 12 patients with progressive supranuclear palsy (PSP), and 13 age‐matched controls, using N‐methyl‐4‐[11C]piperidyl acetate and positron emission tomography. Kinetic analysis was performed to calculate k3, an index of acetylcholinesterase activity. In PD patients, there was a significant reduction (−17%) of cerebral cortical k3 compared with normal controls, whereas there was only a nonsignificant reduction (−10%) of cortical k3 in PSP patients. However, there was a prominent reduction (−38%) of thalamic k3 in PSP patients compared with normal controls, whereas there was only a nonsignificant reduction (−13%) of thalamic k3 in PD patients. The results suggest that there is a loss of cholinergic innervation to the cerebral cortex in association with cholinergic innervation to the thalamus in PD, whereas there is a preferential loss of cholinergic innervation to the thalamus in PSP. When the thalamic to cerebral cortical k3 ratio was taken for each subject, PD and PSP were separated, suggesting that positron emission tomography measurement of acetylcholinesterase activity may be useful for differentiating the two similar disorders. Ann Neurol 1999;46:62–69

[1]  Hitoshi Shinotoh,et al.  Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age , 1999, European Journal of Nuclear Medicine.

[2]  S. Mirra,et al.  The nucleus basalis of Meynert in neurological disease: A quantitative morphological study , 1985, Annals of neurology.

[3]  Sid Gilman,et al.  Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography , 1988, Annals of neurology.

[4]  E. Hirsch,et al.  Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy , 1991, Neuroscience.

[5]  Y. Iwadate,et al.  Quantifying brain tumor blood flow by the microsphere model with N-isopropyl-p-[123I]iodoamphetamine super-early SPECT , 1996, Annals of nuclear medicine.

[6]  E. Hirsch,et al.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy , 1985, Annals of neurology.

[7]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[8]  K. Jellinger,et al.  The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[9]  K. Fukushi,et al.  Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. , 1994, Nuclear medicine and biology.

[10]  B. Snow,et al.  Criteria for diagnosing Parkinson's disease , 1992, Annals of neurology.

[11]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[12]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[13]  J. Rinne,et al.  Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson's disease , 1989, Journal of the Neurological Sciences.

[14]  C. Duyckaerts,et al.  Progressive supranuclear palsy , 1991, Neurology.

[15]  S. Datta,et al.  Excitation of the brain stem pedunculopontine tegmentum cholinergic cells induces wakefulness and REM sleep. , 1997, Journal of neurophysiology.

[16]  Hitoshi Shinotoh,et al.  Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease , 1997, The Lancet.

[17]  Chickering Jg,et al.  Innervation of propatagial musculature in a flying squirrel, Glaucomys volans (Rodentia, Sciuridae). , 1996 .

[18]  J. Grafman,et al.  Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy , 1994, Annals of neurology.

[19]  Y. Kuwabara,et al.  Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy , 1989, Annals of nuclear medicine.

[20]  Bernard Pillon,et al.  Cognitive deficits in Parkinson’s disease , 1996, Journal of Neurology.

[21]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[22]  C. Bouras,et al.  The basal nucleus of Meynert in patients with progressive supranuclear palsy , 1984, Neuroscience Letters.

[23]  E. Perry,et al.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[24]  E. Hirsch,et al.  Mesencephalic cholinergic nuclei in progressive supranuclear palsy , 1991, Neurology.

[25]  E. Perry,et al.  Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases , 1983, Journal of the Neurological Sciences.

[26]  Y. Agid,et al.  Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease , 1986, Brain Research.

[27]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[28]  K. Davis,et al.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. , 1994, Neuroreport.

[29]  M Otsuka,et al.  Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[30]  M. Inase,et al.  Excitotoxic lesions of the pedunculopontine tegmental nucleus produce contralateral hemiparkinsonism in the monkey , 1997, Neuroscience Letters.

[31]  S. Kish,et al.  Progressive supranuclear palsy: Relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers , 1985, Annals of neurology.

[32]  A. Parent,et al.  Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.

[33]  M. Mesulam,et al.  Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6) , 1983, Neuroscience.

[34]  A J Lees,et al.  Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. , 1988, Brain : a journal of neurology.

[35]  S. Minoshima,et al.  In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.

[36]  M. Iyo,et al.  Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  A M Graybiel,et al.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  I. Nakano,et al.  Parhnson’s Disease: Neuron Loss in the Nucleus Basah Without Concomitant Alzheimer’s Disease , 2004 .

[39]  M. Iyo,et al.  In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog , 1994, Brain Research.

[40]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.